ACADIA Pharmaceuticals (ACAD) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.63 earnings per share for the quarter, missing the analyst consensus estimate by $-0.16. Analysts had a consensus of $-0.47. The company posted revenue of $.97 million in the period, compared to analysts expectations of $.71 million. The company’s revenue was up 96900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.39 EPS.
Many Wall Street Analysts have commented on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals was Downgraded by BofA/Merrill to ” Neutral” on Jun 22, 2016.
ACADIA Pharmaceuticals closed down -0.64 points or -1.72% at $36.59 with 16,89,569 shares getting traded on Tusday. Post opening the session at $37, the shares hit an intraday low of $35.32 and an intraday high of $37.1 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jul 13, 2016, Glenn Baity (EVP AND GC) sold 16,000 shares at $35.00 per share price. According to the SEC, on Feb 19, 2015, Uli Hacksell (CEO) sold 30,000 shares at $34.30 per share price.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis Alzheimers disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.